4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat on Wednesday, August 13, 2025, at 2:30 p.m. ET.
The presentation will be available via webcast, and management will be available for one-on-one meetings. An archived recording of the webcast will be accessible for up to one year on the company's investor relations website.
4D Molecular Therapeutics (NASDAQ:FDMT), un'azienda biotecnologica in fase avanzata, ha annunciato la sua partecipazione al 5掳 Congresso Annuale Virtuale di Oftalmologia di H.C. Wainwright. Il management della societ脿 parteciper脿 a una conversazione informale il mercoled矛 13 agosto 2025, alle 14:30 ET.
La presentazione sar脿 trasmessa in webcast e il management sar脿 disponibile per incontri individuali. Una registrazione archiviata del webcast sar脿 accessibile per un anno sul sito web delle relazioni con gli investitori della societ脿.
4D Molecular Therapeutics (NASDAQ:FDMT), una empresa biotecnol贸gica en fase avanzada, anunci贸 su participaci贸n en la 5陋 Conferencia Anual Virtual de Oftalmolog铆a de H.C. Wainwright. La direcci贸n de la empresa participar谩 en una charla informal el mi茅rcoles 13 de agosto de 2025, a las 2:30 p.m. ET.
La presentaci贸n estar谩 disponible v铆a webcast y la direcci贸n estar谩 disponible para reuniones individuales. Una grabaci贸n archivada del webcast estar谩 accesible durante un a帽o en el sitio web de relaciones con inversores de la empresa.
4D Molecular Therapeutics (NASDAQ:FDMT), 頉勱赴 雼硠 靸濍獏瓿淀暀 須岇偓臧� H.C. Wainwright 鞝�5須� 鞐半 鞎堦臣 臧�靸� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳潃 2025雲� 8鞗� 13鞚� 靾橃殧鞚� 鞓ろ泟 2鞁� 30攵�(霃欕秬鞁滉皠)鞐� 頇旍儊 雽�頇旍棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞝滉车霅橂┌, 瓴届榿歆勳潃 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼 雲鬼檾氤胳潃 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 斓滊寑 1雲勱皠 氤� 靾� 鞛堨姷雼堧嫟.
4D Molecular Therapeutics (NASDAQ:FDMT), une entreprise biotechnologique en phase avanc茅e, a annonc茅 sa participation 脿 la 5e Conf茅rence Annuelle Virtuelle d'Ophtalmologie H.C. Wainwright. La direction de l'entreprise participera 脿 une discussion informelle le mercredi 13 ao没t 2025 脿 14h30 ET.
La pr茅sentation sera disponible en webcast, et la direction sera disponible pour des r茅unions individuelles. Un enregistrement archiv茅 du webcast sera accessible pendant un an sur le site des relations investisseurs de l'entreprise.
4D Molecular Therapeutics (NASDAQ:FDMT), ein Biotechnologieunternehmen in der Sp盲tphase, gab seine Teilnahme an der 5. j盲hrlichen virtuellen Ophthalmologie-Konferenz von H.C. Wainwright bekannt. Das Management des Unternehmens wird am Mittwoch, den 13. August 2025, um 14:30 Uhr ET an einem Gespr盲ch am Kamin teilnehmen.
Die Pr盲sentation wird per Webcast verf眉gbar sein, und das Management steht f眉r Einzelgespr盲che zur Verf眉gung. Eine archivierte Aufzeichnung des Webcasts wird bis zu einem Jahr auf der Investor-Relations-Website des Unternehmens zug盲nglich sein.
- None.
- None.
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics聽(Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the H.C. Wainwright 5th聽Annual Ophthalmology Virtual Conference.聽Members of the management team will also be available for one-on-one meetings.
H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
| Presentation Date: | Wednesday, Aug 13, 2025 |
| Presentation Time: | 2:30 p.m. ET |
| Webcast Link: |
An archived copy of the webcast will be available for up to one year on the 鈥淚nvestors鈥� section of the 4DMT website at .
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company鈥檚 lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company鈥檚 lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company鈥檚 second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics鈩�, 4DMT鈩�, Therapeutic Vector Evolution鈩�, and the 4DMT logo are trademarks of 4DMT.
All of the Company鈥檚 product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company鈥檚 product candidates for the therapeutic uses for which they are being studied.
Learn more at and follow us on .
Contacts:
Media:
Jenn Gordon
dna Communications
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the H.C. Wainwright Ophthalmology Conference?
Where can I watch the FDMT presentation at the H.C. Wainwright Conference?
What type of presentation will FDMT give at the H.C. Wainwright Conference?
How long will FDMT's H.C. Wainwright Conference presentation be available to view?
